High mortality following unplanned breast cancer hospitalizations.

R Raissa G. Carneiro (Instituto Nacional de Câncer - INCA, Rio De Janeiro, Brazil) M Marcella Oliveira Rabelo Amaral (Instituto Nacional de Câncer - INCA, Rio De Janeiro, Brazil) A Alex Pereira Ramos (Instituto Nacional de Câncer - INCA, Rio De Janeiro, Brazil) P Pedro Bergmann (Instituto Nacional de Câncer - INCA, Rio De Janeiro, Brazil) H Hanna Salomão Silva (Instituto Nacional do Câncer - INCA, Rio De Janeiro, Brazil) R Rafaela Milagres Santana (Instituto Nacional do Câncer - INCA, Rio De Janeiro, Brazil) M Mariana Vargas Gil (Instituto Nacional do Câncer - INCA, Rio De Janeiro, Brazil) I Isabele A. Small (Instituto Nacional do Cancer, Rio De Janeiro, Brazil) N Nathália Silva de Paula (Instituto Nacional do Câncer - INCA, Rio De Janeiro, Brazil) S Sarah Adelaide De Menezes Campos (Brazilian National Cancer Institute - Inca, Rio De Janeiro, Brazil) M Mariana Rodrigues (Instituto Nacional do Câncer - INCA, Rio De Janeiro, Brazil) J José Bines

Abstract

e23408 Background: The majority of breast cancer care occurs in outpatient settings, and data derived from hospital admissions remain scarce. Methods: A retrospective analysis was perfomed of unplanned admissions to a dedicated breast cancer unit at the National Cancer Institute, Brazil, over 18 months period. Demographic, clinical, and hospitalization characteristics were examined. Causes of admission were classified as disease progression, treatment-related toxicity, or non-oncologic complications. The primary outcome was in-hospital mortality, evaluated using multivariable logistic regression. Results: A total of 731 patients were included, accounting for 1053 unplanned admissions. Self-reported race was Black, White, and Asian in 62.1%, 37.5%, and 0.4% of patients, respectively. Median age at diagnosis was 54 years (IQR, 45.0–63.5). Most patients had advanced disease (stage III: 44.7%; stage IV: 27.3%). Tumor subtypes were hormone receptor–positive/HER2-negative in 59.4%, HER2-positive in 21.6%, and triple-negative in 14.8%. Most patients experienced one unplanned hospitalization (71.7%); 19.7% had two, and 8.6% had three or more. The median length of stay was 8 days (IQR, 5–13.0), and the median time to death was 8 days (IQR, 4–17). Readmissions occurred in 28.3% of patients, including 14.1% within 30 days. Admissions were mainly due to disease progression (63.0%); followed by non-oncologic complications (22.7%), and treatment-related toxicity (14.2%). In-hospital mortality was 39.1% and independent predictors of death were age (OR 1.02, 95% CI 1.00–1.03; p = 0.019), number of hospitalizations (OR 1.51, 95% CI 1.21–1.92; p = 0.001), poor performance status at the last admission (ECOG ≥2; OR 4.92, 95% CI 2.64–9.89; p < 0.001), last admission due to disease progression (OR 2.90, 95% CI 1.88–4.53; p < 0.001). These variables were adjusted by tumor subtype, and ongoing treatment during the last hospitalization. Conclusions: Unplanned admissions to a dedicated breast cancer unit were associated with high in-hospital mortality, particularly among patients with advanced disease, poor performance status, and repeated admissions. Early identification of high-risk patients may facilitate timely integration of palliative care strategies.

Article Details

Volume / Issue Vol. 44, Issue 16_suppl
Published June 01, 2026
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (12)

R

Raissa G. Carneiro

Instituto Nacional de Câncer - INCA, Rio De Janeiro, Brazil

M

Marcella Oliveira Rabelo Amaral

Instituto Nacional de Câncer - INCA, Rio De Janeiro, Brazil

A

Alex Pereira Ramos

Instituto Nacional de Câncer - INCA, Rio De Janeiro, Brazil

P

Pedro Bergmann

Instituto Nacional de Câncer - INCA, Rio De Janeiro, Brazil

H

Hanna Salomão Silva

Instituto Nacional do Câncer - INCA, Rio De Janeiro, Brazil

R

Rafaela Milagres Santana

Instituto Nacional do Câncer - INCA, Rio De Janeiro, Brazil

M

Mariana Vargas Gil

Instituto Nacional do Câncer - INCA, Rio De Janeiro, Brazil

I

Isabele A. Small

Instituto Nacional do Cancer, Rio De Janeiro, Brazil

N

Nathália Silva de Paula

Instituto Nacional do Câncer - INCA, Rio De Janeiro, Brazil

S

Sarah Adelaide De Menezes Campos

Brazilian National Cancer Institute - Inca, Rio De Janeiro, Brazil

M

Mariana Rodrigues

Instituto Nacional do Câncer - INCA, Rio De Janeiro, Brazil

J

José Bines